CCR7 and neoplasm: Lower target density in non-tumor cells or lower affinity of these antibodies for CCR7 expressed in these cell types could explain these observations which also suggests that anti-CCR7 therapy might impair new immunization processes dependent on TN cells, but not memory effector responses against infections (273–275).